Investor Presentaiton
For personal use only
TLX101-CDx / TLX101 overview
Orphan designation status granted for imaging and therapy candidates
.
Target: Large amino acid transporter 1 (LAT-1)
Indication: Glioblastoma multiforme (GBM)
Clinical status:
TELIX
PHARMACEUTICALS
Dx
Tx
Target: LAT-1
(TLX101-
CDX)
(TLX101)
•
•
•
TLX101-CDx: Progressing towards new drug application (NDA)
filing in 2022
Targeting molecule
Small molecule Small molecule
•
TLX101: IPAX-2 follow-on Phase I/II study in newly diagnosed
patients commencing in 2022.
Fluoroethyl)-L- 4-L-[131] lodo-
Targeting agent
tyrosine (FET)
Phenylalanine
•
Rationale:
TLX101-CDX: FET-PET demonstrated to provide greater
diagnostic sensitivity compared to standard imaging procedures
TLX101: Poor prognosis with few treatment options. Promising
overall survival data in IPAX-1 study warrants further
investigation in earlier stage patients
Telix Pharmaceuticals Limited (ASX: TLX)
Radionuclide
18F
131
46View entire presentation